TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06233175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined kinetic chain exercises
Description: combined kinetic chain exercises in form of wall slide ,terminal knee extension ,forward step up and down ,side step up and down ,straight leg raise ,seated knee extension ,stretching exercises , hot back and trans cutaneous electrical stimulation,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: stretching exercises and hot back and trans cutaneous electrical stimulation,with out combined kinetic chain exercises
Study: NCT04965038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Intravenous thrombolysis with alteplase within 4.5 hours of symptom onset
Study: NCT05461092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delirium Rating Scale-Revised-98 (DRS)
Description: 16 item clinician rated scale assessing delirium severity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Interview for Cognitive Status - Modified (TICS-M)
Description: Telephone interview questionnaire evaluating patient cognitive status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Interview for Cognitive Status - Modified (TICS-M)
Description: Telephone interview questionnaire evaluating patient cognitive status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Equivalents measured by Morphine Milligram Equivalents (MME)
Description: The amount of opioids administered will be collected through patient self-report
Study: NCT01710865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultraseal Sealant
Description: This is a newly developed hydrophilic sealant material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultraseal Sealant
Description: This is a previously existing hydrophobic sealant material.
Study: NCT05461092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Equivalents measured by Morphine Milligram Equivalents (MME)
Description: The amount of opioids administered will be collected through patient self-report

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire depression scale (PHQ-8)
Description: Questionnaire used to diagnose and determine the severity measure for depressive disorders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Health Questionnaire depression scale (PHQ-8)
Description: Questionnaire used to diagnose and determine the severity measure for depressive disorders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing
Description: Scale used to determine pain catastrophizing and it's severity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Catastrophizing
Description: Scale used to determine pain catastrophizing and it's severity.
Study: NCT05437510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Description: Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
Study: NCT06528327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre coated impants
Description: Pre coated impants with microstructured bioactive antimicrobial coating with double threading for higher bone-to-implant contact and faster bone gathering on the surface.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non coated implant surface
Description: Non-coated implant with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
Study: NCT05760482

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Metobolites serum level measurement
Description: Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Metobolites serum level measurement
Description: Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety and stress level measurement
Description: Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety and stress level measurement
Description: Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
Study: NCT05483426

Intervention type: OTHER
Group type: OTHER
Intervention: semi-structured Interviews
Description: semi-structured interview conducted by a psychiatrist
Study: NCT06512662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consultations with paramedics
Description: Patients of experimental arm will beneficiate of supplemental consultations with paramedics intervenants at 1 month, 3 months and 6 months after surgery :~* dietetician~* speech therapist~* psychologist~* advanced practice nurse~During these consultations, several scales will be performed to assess the patient's condition (anxiety, nutritional status, psychological condition, speech therapy status).
Study: NCT06567509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises and Short foot exercises
Description: Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises and Short foot exercises
Description: Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional foot exercises and short foot exercises
Description: Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional foot exercises and short foot exercises
Description: Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises
Study: NCT05461092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fear Avoidance Beliefs Questionnaire (FABQ)
Description: Questionnaire used to help predict patients that have a high pain avoidance behavior.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fear Avoidance Beliefs Questionnaire (FABQ)
Description: Questionnaire used to help predict patients that have a high pain avoidance behavior.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Side Effects and Likeability Questionnaire
Description: Survey determining adverse events related to opioid side effects and complications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Side Effects and Likeability Questionnaire
Description: Survey determining adverse events related to opioid side effects and complications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Pain Trajectory
Description: Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
Study: NCT02840214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
Study: NCT06684613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrEP Decision Aid
Description: Patient-facing decision-aid on PrEP that is already gender- and trauma- responsive and will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of contraceptive counseling.

Intervention type: OTHER
Group type: OTHER
Intervention: Generic Information
Description: Participants will be asked to watch a CDC-produced video, PrEP (Pre-Exposure Prophylaxis (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid.
Study: NCT06396221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol 15 mg/Drospirenone 3 mg (24/4)
Description: Completing a pack (28 pills) of Estetrol 15 mg/Drospirenone 3 mg (24/4), starting on day 7-9 of menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)
Description: Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
Study: NCT06701981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filter comparison
Description: Three filters will be compared on light discomfort thresholds using the Lumiz 100™ device
Study: NCT06700954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: legume-rich Planetary Health Diet
Description: legume-rich diet based on the Planetary Health Diet, with a focus on vegetable protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control diet based on Western Diet low in legumes
Description: diet based on the Western dietary pattern including animal protein sources (= control diet)
Study: NCT06703476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent placement
Description: Surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: Patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses).
Study: NCT06703112

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: An auxiliary diagnostic model for ovarian tumors
Description: Through collaboration among gynecological oncology teams from three research centers, the multimodal ovarian tumor auxiliary diagnosis system will undergo multicenter, prospective clinical application, with surgical pathology results used as the gold standard. The diagnostic performance of the multimodal ovarian tumor auxiliary diagnosis system, both overall and across different pathological categories, will be evaluated in the main and subsidiary centers by comparing metrics such as specificity, sensitivity, positive predictive value, negative predictive value, and area under the ROC curve (AUC).
Study: NCT04968743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
Study: NCT03910010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
Study: NCT05385744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132
Description: anti-CD20 monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Teriflunomide 14 mg
Study: NCT05166421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: AZD7442 will be administered via IM route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD8895 (clonal cell line material)
Description: AZD8895 will be administered via IM route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1061 (clonal cell line material)
Description: AZD1061 will be administered via IM route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD8895 (cell pool material)
Description: AZD8895 will be administered via IM route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1061 (cell pool material)
Description: AZD1061 will be administered via IM route.
Study: NCT06525155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Embonate
Description: Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Embonate
Description: Treatment 2: 3.75 mg once after surgery at week-12
Study: NCT06482437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets taken twice daily for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken twice daily for 21 days
Study: NCT05408728

Intervention type: PROCEDURE
Intervention: Endoscopic biopsy
Description: Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption

Intervention type: PROCEDURE
Intervention: Endoscopic biopsy
Description: Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption
Study: NCT06480565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-270
Description: Anti-CD70 CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-270
Description: Anti-CD70 CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepeletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepeletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion
Study: NCT06368778

Intervention type: OTHER
Intervention: Verbal Advice
Description: The participant will receive verbal instructions following the standard physical therapy.

Intervention type: OTHER
Intervention: Bathroom Scale
Description: The participant is given a sense of what a 20 kg load feels like using a scale.

Intervention type: DEVICE
Intervention: Loadsol Biofeedback
Description: Average peak force (N) with be measured during partial weightbearing physical therapy routine for 2-minutes using the Loadsol device.
Study: NCT05940870

Intervention type: DEVICE
Intervention: Nerivio
Description: Patients with migraine who received the Nerivio device for migraine prevention therapy
Study: NCT04424407

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
Study: NCT06134765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemalenograstim alfa
Description: Bemalenograstim alfa,20mg, once every treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemalenograstim alfa
Description: Bemalenograstim alfa,20mg, once every treatment
Study: NCT04876859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRF of anterior sensitive branches to the hip
Description: Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Anesthetic block with steroid injection of anterior sensitive branches to the hip
Description: Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
Study: NCT05365347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Description: Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
Study: NCT06536686

Intervention type: GENETIC
Intervention: Silent myocardial ischemia, STEMI
Description: Silent myocardial ischemia association with genetic polymorphisms, miRNA and EVs

Intervention type: GENETIC
Intervention: Silent myocardial ischemia, STEMI
Description: Silent myocardial ischemia association with genetic polymorphisms, miRNA and EVs
Study: NCT04955873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of the dental extraction socket using newly-released biomaterials
Description: Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of the dental extraction socket using well-known biomaterials
Description: Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
Study: NCT06567795

Intervention type: DEVICE
Intervention: Hemotag
Description: Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days
Study: NCT06460246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter
Description: The subjects will have a 22-gauge catheter inserted in the radial artery to measure the oxygen saturation of arterial blood and also wear pulse oximeters.
Study: NCT04976387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET
Description: Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET
Description: Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Patients will take ibuprofen 600 mg every 6 hours as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Patients will take ibuprofen 600 mg every 6 hours as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Patients will take ibuprofen 600 mg every 6 hours as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 MG
Description: Patients will take Tylenol 650mg every 6 hours as needed
Study: NCT05928078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention
Description: Participants will be required to use the MOVI-ageing platform 3 times a week for 12 weeks. The platform will include videos of cognitively demanding physical activities designed and guided by health professionals, who will also be able to check compliance with the intervention.